Literature DB >> 10859584

INR self-management following mechanical heart valve replacement.

H Koertke1, K Minami, A Bairaktaris, O Wagner, R Koerfer.   

Abstract

INR self-management can reduce severe thromboembolic and hemorrhagic complications following mechanical heart valve replacement. Beginning anticoagulation therapy immediately in the postoperative period further reduces anticoagulant-induced complications. Data were collected from the first 600 surviving patients (from a total study sample of 1200 patients) who completed follow-up of at least 2 years. Patients were randomly divided into a self-management group and a control group. INR self-management reduced severe hemorrhagic and thromboembolic complications (P=0.018). Nearly 80% of INR values recorded by patients themselves, regardless of educational level, were within the target therapeutic range of INR 2.5-4.5, compared with 62% of INR values monitored by family practitioners. Only 8.3% of patients trained in self-management immediately after surgery were unable to continue with INR self-management. The results differed slightly between patient groups with different levels of education. We conclude that all patients for whom anticoagulation is indicated are candidates for INR self-management regardless of education level.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859584     DOI: 10.1023/a:1018712520472

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  9 in total

1.  Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group.

Authors: 
Journal:  Lancet       Date:  1982-01-09       Impact factor: 79.321

2.  Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting.

Authors:  F B Davis; M T Estruch; E B Samson-Corvera; G C Voigt; J D Tobin
Journal:  Arch Intern Med       Date:  1977-02

Review 3.  Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.

Authors:  P D Stein; J S Alpert; J Copeland; J E Dalen; S Goldman; A G Turpie
Journal:  Chest       Date:  1995-10       Impact factor: 9.410

4.  A 7-year analysis of haemorrhage in patients on long-term anticoagulant treatment.

Authors:  J C Forfar
Journal:  Br Heart J       Date:  1979-08

Review 5.  Thrombotic and bleeding complications of prosthetic heart valves.

Authors:  L H Edmunds
Journal:  Ann Thorac Surg       Date:  1987-10       Impact factor: 4.330

6.  [Complications of anticoagulant treatment. Report of 98 accidents and incidents (author's transl)].

Authors:  G Gaudel; J Fouchard
Journal:  Sem Hop       Date:  1979 Sep 8-15

7.  A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease.

Authors:  K E Hammermeister; G K Sethi; W G Henderson; C Oprian; T Kim; S Rahimtoola
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

8.  Choosing a substitute cardiac valve: type, size, surgeon.

Authors:  W C Roberts
Journal:  Am J Cardiol       Date:  1976-11-04       Impact factor: 2.778

9.  Problems encountered in long-term treatment with anticoagulants.

Authors:  S Husted; F Andreasen
Journal:  Acta Med Scand       Date:  1976
  9 in total
  14 in total

Review 1.  Anticoagulation in patients with thromboembolic disease.

Authors:  R C Tait
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 2.  Home international normalized ratio monitoring: where evidence-based medicine is exemplified in the Medicare coverage process.

Authors:  Mitchell I Burken; John J Whyte
Journal:  J Thromb Thrombolysis       Date:  2002-02       Impact factor: 2.300

3.  The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS).

Authors:  David B Matchar; Alan K Jacobson; Robert G Edson; Philip W Lavori; Jack E Ansell; Michael D Ezekowitz; Frederick Rickles; Lou Fiore; Kathy Boardman; Ciaran Phibbs; Stephan D Fihn; Julia E Vertrees; Rowena Dolor
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

4.  Economic evaluation of the use of point-of-care devices in patients with long term oral anticoagulation.

Authors:  Sophie Gerkens; Jeannine Gailly; Caroline Obyn; Stephan Devriese; Irina Cleemput
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

5.  Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.

Authors:  Dean A Regier; Rubina Sunderji; Larry D Lynd; Kenneth Gin; Carlo A Marra
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

6.  Feasibility and patients' acceptance of Home Automated Telemanagement of oral anticoagulation therapy.

Authors:  J Finkelstein; R Khare; J Ansell
Journal:  AMIA Annu Symp Proc       Date:  2003

7.  Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation.

Authors:  Susan I O'Shea; Murat O Arcasoy; Gregory Samsa; Sandra E Cummings; Elizabeth H Thames; Richard S Surwit; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2007-07-08       Impact factor: 2.300

8.  Anticoagulant monitoring in ventricular assist device patients: a feasibility study.

Authors:  Ashish Joshi; Diane Smith; Mohit Arora; Robert Poston
Journal:  Interact Cardiovasc Thorac Surg       Date:  2008-09-04

Review 9.  Self-monitoring and self-management of oral anticoagulation.

Authors:  Carl J Heneghan; Josep M Garcia-Alamino; Elizabeth A Spencer; Alison M Ward; Rafael Perera; Clare Bankhead; Pablo Alonso-Coello; David Fitzmaurice; Kamal R Mahtani; Igho J Onakpoya
Journal:  Cochrane Database Syst Rev       Date:  2016-07-05

10.  Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.